Perlmutter Cancer Center

The purpose of this study is to hope that Precision PromiseSM will change the landscape of clinical development in pancreatic cancer and open the door to longer and better lives for all patients with this disease. This platform trial is designed to increase access to therapeutic trials across the pancreatic cancer community and will allow more rapid completion of testing and approval of new therapies. Additionally, the study design reduces clinical trial start-up and execution times and has the potential for rapidly testing multiple combination therapies simultaneously. Lastly, Precision PromiseSM enhances the patient experience as it reduces the number of patients being randomized to standard of care therapies.